Davis Polk advised Kadmon Holdings, Inc. in connection with an $80.4 million offering of 22,275,000 shares of common stock and warrants to purchase 8,910,000 shares of common stock, which included the full exercise of the underwriters’ option to purchase additional shares of common stock and additional warrants. The offerings consisted of an underwritten offering and a registered direct offering to certain institutional investors. The closing of an additional 4,500,000 shares of common stock and warrants to purchase 1,800,000 shares of common stock in the registered direct offering is expected to occur on or about October 10, 2017.

Kadmon is a fully integrated biopharmaceutical company focused on developing innovative products for significant unmet needs within autoimmune and fibrotic diseases.

The Davis Polk corporate team included partners Michael Kaplan and Sophia Hudson and associate Stephen A. Byeff. The tax team included partner Rachel D. Kleinberg and associate Karen Li. The intellectual property and technology team included counsel David R. Bauer and associate Jesse L. Hallock. Associate Brantley Hawkins provided 1940 Act advice. Members of the Davis Polk team are based in the New York and Northern California offices.

Copy link to share post